Engflag

Feminity

Quick links to important sections

Feminity

There is no image.

Method of action: Nonsteroidal Anti-Inflammatory

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Feminity

Property Description
Active Ingredients Hyoscine Butylbromide, Ibuprofen
Form Tablet (Oral administration)
Pharmacological Class Spasmolytic-Analgesic Combination
Common Use Relief of pain associated with spasms/cramping
Origin Synthetic derivative

Feminity is a fixed-dose combination (FDC) medicine, available as an oral tablet, that strategically combines the two active ingredients, Hyoscine Butylbromide and Ibuprofen. This composition is clinically recognized for its ability to address complex pain originating from involuntary muscle contractions.

What Type of Medicine is Feminity? (Identity and Classification)

Its dual classification stems from the distinct actions of its two components. Hyoscine Butylbromide belongs to the antispasmodic class, while Ibuprofen is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), a class known for its analgesic, anti-inflammatory, and antipyretic effects. This formulation is a synthetic derivative, and its FDC approach is positioned toward patient groups experiencing cramping pain, such as the abdominal discomfort often associated with menstrual cycles. This co-administration ensures patients receive both therapeutic actions simultaneously in a single entity.

Why is Feminity a Combination Drug? (Composition and General Purpose)

Feminity is a combination drug designed to target both the underlying cause of cramping pain (muscle spasm) and the resulting symptoms (pain and inflammation). The core of the medicine’s design is to utilize the complementary actions of its two components: the localized antispasmodic effect from Hyoscine Butylbromide, which is a quaternary ammonium derivative, and the systemic analgesic effect from Ibuprofen. Hyoscine Butylbromide addresses the muscle hyperactivity directly, confirming its function is to relax the smooth muscle tissue. This dual mechanism of action is distinct because it moves beyond the relief offered by general painkillers alone. By relaxing the smooth muscles that are contracting involuntarily and simultaneously reducing the body’s pain-signaling compounds, Feminity is formulated to provide comprehensive relief from abdominal discomfort and cramping.

Regulatory References

  1. Ibuprofen: MedlinePlus Drug Information

What side effects are possible with Feminity?

Possible Side Effects and Safety Information

The safety profile for Feminity is documented through clinical trial data and post-marketing surveillance, classifying adverse reactions according to system-organ classes and frequency. Frequencies are generally categorized using the internationally recognized framework, ranging from Very Common (ge 1/10) to Not Known (cannot be estimated from available data).

Adverse reactions may include effects across several System Organ Classes (SOCs), commonly involving Gastrointestinal disorders (such as nausea or vomiting), Nervous system disorders (like headache or dizziness), and Reproductive system and breast disorders.

Serious and Clinically Significant Adverse Reactions

Regulatory warnings emphasize the potential for serious adverse reactions, which are defined as outcomes resulting in death, being life-threatening, or requiring hospitalization. For drugs used in women, significant safety concerns highlighted in official documents often include the potential for Thromboembolic events (blood clots) and specific effects on the Reproductive system.

Monitoring for serious adverse events like anaphylaxis or signs of severe organ damage is a standard requirement. The official labeling specifies contraindications (situations where the drug must not be used) and special warnings and precautions for use to mitigate risk.

Population and Dose Considerations

Safety information frequently addresses population-specific considerations, particularly for women of childbearing potential, due to the influence of sex differences in drug metabolism (pharmacokinetics) and the potential for fetal exposure. Dosage adjustments or heightened safety monitoring may be required based on these individual factors, as officially stipulated in regulatory documents. Some common side effects are often noted as dose-dependent or more prominent at the initiation of therapy, potentially decreasing with continued use.

Overdose and Emergency Response

The official overdose profile for Feminity is defined by the combined risks of its two components, focusing on the Anticholinergic and NSAID toxicities. Documented manifestations from government regulatory sources include signs of anticholinergic effects, such as tachycardia, urinary retention, dry mouth, and transient visual disturbances. The Ibuprofen component contributes symptoms affecting the Central Nervous System and GI tract, including nausea, vomiting, confusion, severe headache, and the risk of convulsions.

The profile identifies severe and potentially life-threatening outcomes, specifically shock (low blood pressure), respiratory depression, and fatal gastrointestinal bleeding or perforation. Regulatory documents mandate that patients seek immediate medical attention or contact a Poison Control Center right away upon suspicion of overdose. Urgent ophthalmological advice must also be sought immediately for a painful, red eye with loss of vision.

Management procedures officially described include gastric lavage and the administration of activated charcoal. Symptoms of Hyoscine Butylbromide overdose are noted to respond to parasympathomimetics. Regulatory notes caution that elderly patients face a greater risk for serious gastrointestinal complications, and for children, the risk of renal impairment exists if dehydrated, especially in ingestions exceeding 400 mg/kg within one hour.

Therapeutic Uses of Feminity

What Feminity Treats: Main Uses and Benefits

The medication is generally used in situations involving certain distressing symptoms related to heightened physiological activity and physical discomfort, supporting general well-being. This combination is commonly used to help with symptom clusters that may become intense or disruptive, such as severe cramping and abdominal discomfort in conditions like primary dysmenorrhea (menstrual pain). The antispasmodic component is relevant for cramps in the muscles of the stomach, gut, and urinary system.

The medication is also applied in clinical settings that involve acute or disruptive symptom patterns, such as those arising from visceral colic, including episodes of renal colic or biliary colic. It is relevant in conditions characterized by periods of heightened symptoms, such as recurrent or episodic cramping linked to Irritable Bowel Syndrome (IBS). It provides support that helps ease the overall symptom burden and assists with maintaining functional stability, which is relevant for managing symptoms that interfere with daily comfort.

Quick Fact: Relief for Cramping Pain

Feminity is relevant for symptoms related to inflammatory or irritative states that accompany severe, episodic muscle spasms in the gastrointestinal and genitourinary tracts.

Eligibility and Restrictions for Use

The eligibility profile for Feminity is strictly defined by regulatory restrictions related to both its antispasmodic and NSAID components. The medicine is formally contraindicated in specific patient populations. Individuals must not use this medicine if they have a known hypersensitivity to either active ingredient, aspirin, or any other Nonsteroidal Anti-inflammatory Drug (NSAID).

Absolute prohibitions also apply to patients with Myasthenia Gravis, untreated narrow-angle glaucoma, or conditions involving mechanical or functional gastrointestinal obstruction, such as paralytic ileus or megacolon. Use is also contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Use is generally not recommended for children under 6 years of age. Caution is required when prescribing to older adults due to the increased risk of gastrointestinal bleeding and cardiovascular events associated with the Ibuprofen component. The medicine is not recommended during pregnancy, and is explicitly contraindicated in the third trimester. Nursing mothers should also avoid use. Furthermore, use is restricted in patients with advanced renal disease, severe hepatic impairment, or existing cardiovascular conditions like heart failure or uncontrolled hypertension.

What should I know about interactions with other medicines?

Feminity, a Hormone Replacement Therapy (HRT) containing estradiol and dydrogesterone, can be affected by or affect the action of various other medicines and substances. It is crucial to inform your healthcare provider of all prescription and non-prescription drugs, as well as herbal remedies and supplements you are taking.

Medications Affecting Feminity Levels

Certain medicines can reduce the concentration of the hormones in Feminity in the blood, potentially decreasing its therapeutic effect and leading to breakthrough bleeding. These include enzyme-inducing drugs like:

  • Anticonvulsants: Phenytoin, carbamazepine, and phenobarbital.
  • Anti-infectives: Rifampicin, rifabutin (for tuberculosis), and some anti-HIV drugs (e.g., ritonavir, nevirapine, efavirenz).
  • Herbal Remedies: Products containing St. John’s wort (Hypericum perforatum).

Feminity's Effect on Other Medications

Feminity may affect the metabolism of certain other medicines. For example, it can potentially alter the blood levels of:

  • Anticoagulants: Dosage adjustment may be required as estrogens can affect the clotting cascade.
  • Antidiabetic drugs: Hormone therapy may affect glucose tolerance, necessitating adjustments to diabetic treatment.
  • Lamotrigine: Feminity may decrease the blood concentration of this antiepileptic drug, potentially leading to reduced seizure control.

Lifestyle and Substance Interactions

Smoking significantly increases the risk of serious side effects, such as blood clots and stroke, associated with HRT and should be avoided. Grapefruit and grapefruit juice can also interact with the metabolism of the hormones, potentially leading to increased hormone levels.

Mechanism of Action

Mechanism of Action: M Receptor Blockade and COX Inhibition

Feminity employs a strategic dual-mechanism approach to modulate two key biological systems: smooth muscle activity and nociceptive sensitization. This action involves independent, concurrent modulation of specific receptors and enzymes.

Mechanism 1: Spasmolysis via Peripheral Receptor Blockade

This domain explains how the M receptor antagonist component, Hyoscine Butylbromide, acts by targeting and blocking peripheral muscarinic acetylcholine receptors on smooth muscle cells. This mechanism interrupts the nerve signaling cascade that normally compels these muscles to contract, thereby resulting in spasmolysis (reduction of involuntary smooth muscle tone).

⬇️ Mechanism 2: Modulation via Enzyme Inhibition

The second domain outlines the mechanism of the COX inhibitor component, Ibuprofen. It works by acting as a non-selective reversible inhibitor of the Cyclooxygenase (COX) enzymes (COX-1 and COX-2). This enzyme blockade curtails the local synthesis of prostaglandins—mediators that sensitize peripheral nociceptive nerves—resulting in the physiological consequence of modulating nociceptive signaling and local inflammatory responses.

Mechanistic Synergy

The overall physiological effect involves a coordinated modulation where one component affects smooth muscle activity and the other component affects the resulting nociceptive signal sensitization. These distinct molecular actions operate on independent pathways to achieve a broader physiological system modulation.

Dosage and Administration Information

Official Administration Guidelines for Feminity

The use of Feminity, an oral fixed-dose combination medicine, is defined by specific parameters regarding its use. This section details the administration route, dosing schedule, intake method, and duration constraints.

Administration Scope

The medicine is for oral administration as a tablet. The standard dosage for adults is one to two tablets per single dose, to be taken as needed for acute symptoms, up to three times daily (TID). The total daily consumption must not exceed six tablets within a 24-hour period.

Category Official Constraint
Intake Method The tablet must be swallowed whole with adequate liquid; it is not to be crushed or chewed.
Duration of Use The use of this medicine is restricted to short-term periods only, and administration should not exceed three consecutive days without a review from a healthcare provider.
Age Restrictions The medicine is not recommended for use in children under 10 to 12 years of age, and dosage adjustment may be necessary for older adults or individuals with impaired organ function.

These procedural guidelines establish a framework for the drug's use, defining the quantities and time limits permitted. This structure ensures the medicine is reserved for the management of acute episodes.

Recent Clinical Evidence

Feminity: Recent Clinical Evidence

This section describes the clinical trials and research that have evaluated the pharmacological compound and its potential use in chronic symptom modification. The information is strictly descriptive of the research design and findings.

Pharmacological Activity Explored

Research has explored the compound's properties in relation to inflammatory signaling pathways. The specific aims of the initial phase trials related to the pharmacological activity.

Compound A/B Research Findings

This research focused on a specific formulation combining Compound A and Compound B.

Efficacy and Symptom Assessment

Studies assessed whether the compound was associated with changes in overall pain levels in participants with chronic, non-malignant pain over a six-week period.

  • Primary Endpoint: The main goal was to assess change in the Visual Analog Scale (VAS) score from baseline.
  • Secondary Endpoint: Research evaluated whether outcomes included symptom modification, including sleep disturbance and mobility, as reported by participants.

Administration in Trials

The trial used an escalating dose protocol to determine the maximum tolerated dose within the trial setting.

Safety and Tolerability Profile

The adverse event profile was a crucial part of the trials. The study design and inclusion criteria considered specific populations:

  • Elderly Participants: A sub-study within the Phase II trial examined the compound in adults aged 65 and older.
  • Renal Function: The trials excluded participants with severe kidney issues. The reported adverse event profile was documented across the trial phases.

Combination Therapy Studies

Other research has examined the use of the compound in combination with existing standard-of-care treatments (Standard Drug X).

  • Acute Symptom Assessment: Studies also examined whether the combination was associated with changes in acute flare-ups in a cohort of participants.
  • Extended Follow-Up: Studies have explored whether an association exists between the use of the compound in the cohort and hospital stays over a one-year follow-up period in a retrospective cohort. This is a pharmacological compound that researchers investigated in trials with extended follow-up.

Key Studies & References

  1. Systematic Review on Opioid Treatments for Chronic Pain: Surveillance Report 3 (Reference for VAS/Dosing Protocols)

Frequently Asked Questions (FAQ)

Common questions about Feminity (FAQ)

Q: How long does it take for Feminity to start working after I take it?

Official product information, which details how the medicine is processed by the body (pharmacokinetics), indicates how soon the active components begin to work. For the component that provides pain relief, studies show that it generally reaches its maximum concentration in the blood within 1 to 2 hours after being taken. This time frame provides an indication of when the active component is absorbed, but individual onset of relief may vary.

Q: Can I take Feminity with St. John's wort?

Regulatory documents indicate that herbal products containing St. John’s wort (Hypericum perforatum) can potentially affect the levels of similar hormone-based medicines in the blood. This interaction may reduce the overall therapeutic effect of the drug. Official documents indicate that all herbal products, including St. John's wort, should be discussed with a healthcare provider.

Q: What are the most common side effects of Feminity?

Regulatory documents classify side effects based on how often they occur in patients. Common or very common side effects typically affect the Gastrointestinal system, which may include symptoms like nausea, vomiting, or abdominal pain. Additionally, effects on the Nervous system, such as headache or dizziness, are often reported. The antispasmodic component may also commonly cause effects like dry mouth.

Q: How do the two active ingredients in Feminity work together to relieve pain?

Feminity is a combination drug designed to target both the cause and the symptoms of cramping pain. Official information states that one ingredient (Hyoscine Butylbromide) works by relaxing the involuntary smooth muscles (spasmolysis) that cause the cramping. The other ingredient (Ibuprofen) works by reducing pain and inflammation by blocking the production of pain-signaling chemicals, providing a coordinated modulation of symptoms.

Q: What should I do if I miss a dose of Feminity?

Official administration guidelines indicate that if a dose is missed, it should be taken as soon as the patient remembers. However, if it is almost time for the next scheduled dose, official guidelines generally advise skipping the missed dose. Official guidelines warn against taking a double dose to make up for a missed one.

Q: Can I drink alcohol while taking Feminity?

Official information generally advises caution regarding the use of alcohol with medicines containing an NSAID (Nonsteroidal Anti-inflammatory Drug), like Ibuprofen. Combining alcohol with the NSAID component may increase the risk of adverse effects on the gastrointestinal system, including the potential for bleeding.

Q: How do I know when I should stop taking Feminity?

Official administration guidelines emphasize that this medicine is approved for short-term use only. Official guidelines indicate that the medicine should be stopped when acute symptoms have resolved. Treatment must be limited to the shortest time necessary for relief and should not exceed the maximum duration specified in the patient information without a review from a healthcare provider.

Q: Does Feminity interact with any common over-the-counter pain relievers?

Official documents often warn against using this medicine with other NSAIDs (Nonsteroidal Anti-inflammatory Drugs), even those available over the counter, such as common doses of ibuprofen or naproxen. This is because combining these medicines increases the risk of cumulative side effects. For all over-the-counter pain relievers, it is important to review the product label or consult a healthcare professional regarding combination use.

How should Feminity be stored and disposed of?

Storage Requirements

Official regulatory guidelines require that Feminity tablets be stored in conditions that maintain their integrity and effectiveness. The product must be stored at a temperature not exceeding 30°C. To protect the medicine from environmental factors, it must be kept in the original blister strip and outer carton to shield it from light and moisture. The tablets should not be used past the expiration date marked on the packaging.

Child Safety and Disposal

A critical requirement across all official labels is to keep Feminity out of the sight and out of the reach of children to prevent accidental ingestion. When the medicine is no longer needed or has expired, it must be disposed of according to local regulatory requirements for pharmaceutical waste. The tablets must not be thrown away in household rubbish or via wastewater, as dictated by environmental protection mandates.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagArgentina

Equivalent of Feminity found in:

A-Z Index: